| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | n/a | n/a |
| Intrinsic value (DCF) | 1.27 | -73 |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
Lisata Therapeutics, Inc. (NASDAQ: LSTA) is a clinical-stage biopharmaceutical company pioneering innovative cellular therapies to reverse disease and regenerate damaged tissue. Headquartered in Basking Ridge, New Jersey, Lisata focuses on developing breakthrough treatments for critical conditions such as critical limb ischemia (CLI), coronary microvascular dysfunction (CMD), and chronic kidney disease (CKD). Its lead candidate, HONEDRA, has received SAKIGAKE designation in Japan and is in Phase II trials for CLI, while XOWNA targets CMD in Phase IIb trials. Formerly known as Caladrius Biosciences, the company rebranded in 2022 to reflect its advanced therapeutic pipeline. Operating in the high-growth biotechnology sector, Lisata leverages cutting-edge cell therapy platforms to address unmet medical needs, positioning itself as a potential disruptor in regenerative medicine. With a market cap of approximately $23 million, Lisata represents a high-risk, high-reward opportunity in the evolving cell therapy space.
Lisata Therapeutics presents a speculative investment opportunity with significant binary upside tied to clinical trial outcomes. The company's pipeline, particularly HONEDRA with its SAKIGAKE designation, offers potential first-mover advantages in niche vascular indications. However, with $19.4M in net losses (TTM) and only $16.2M in cash, the company faces substantial funding risks ahead of pivotal trials. The lack of revenue-generating products and dependence on successful trial results make this suitable only for risk-tolerant investors. The 0.95 beta suggests market-neutral volatility, but biotech trial catalysts could drive outsized moves. Investors should monitor cash runway and Phase II data readouts closely.
Lisata competes in the specialized cell therapy segment of the biotech industry, differentiating itself through platform technologies targeting vascular regeneration. Its competitive edge stems from: 1) SAKIGAKE designation for HONEDRA, potentially accelerating Japanese approval, 2) a focus on CD34+ cell therapies with demonstrated safety profiles, and 3) niche indications with limited treatment options. However, the company faces challenges from larger biopharma firms with deeper pipelines and financial resources. Lisata's small market cap limits commercial infrastructure, making partnership strategies critical. The competitive landscape requires rapid clinical execution, as several competitors are advancing alternative approaches to vascular repair. Lisata's asset-specific advantages could attract acquisition interest if clinical data are positive, but the company must navigate a crowded regenerative medicine field where many candidates fail in late-stage trials. Its capital efficiency (low debt) is offset by constrained resources for parallel program development.